<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Maio M</dc:creator>
  <dc:creator>Coukos G</dc:creator>
  <dc:creator>Ferrone S</dc:creator>
  <dc:creator>Fox BA</dc:creator>
  <dc:creator>Fridman WH</dc:creator>
  <dc:creator>Garcia PL</dc:creator>
  <dc:creator>Lahn M</dc:creator>
  <dc:creator>Provendier O</dc:creator>
  <dc:creator>Russo V</dc:creator>
  <dc:creator>Rüttinger D</dc:creator>
  <dc:creator>Shalabi A</dc:creator>
  <dc:creator>Trajanoski Z</dc:creator>
  <dc:creator>Viallet J</dc:creator>
  <dc:creator>Wolchok JD</dc:creator>
  <dc:creator>Ibrahim R</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/27812</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00262-018-2285-y</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30564889</dc:relation>
  <dc:source>Cancer immunology, immunotherapy : CII. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Biomarkers</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">CTLA-4</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Immunotherapy</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">OX-40</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">PD-1</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">PD-L1</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Biomarkers, Tumor</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Diffusion of Innovation</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Immunotherapy</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Italy</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Medical Oncology</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Neoplasms</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Translational Medical Research</dc:subject>
  <dc:title xmlns:ns15="xml" ns15:lang="en">Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
